8-K filed Aug 4, 2026 at 06:47 ET
Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus of $16.37B, and non-GAAP EPS of -$0.13 vs consensus -$0.26 (a 50% beat). The company raised its full-year sales guidance to $66.3B-$67.3B but lowered non-GAAP EPS guidance to $2.66-$2.76 due to $2.31/share charge from the Terns acquisition. Operational strength in oncology (KEYTRUDA QLEX uptake, WINREVAIR +75%) and new product launches (LIPFENDRA approval) was offset by acquisition-related losses and declining legacy franchises (GARDASIL, JANUVIA).